Last reviewed · How we verify
Escalation Therapies Group
Escalation Therapies Group is a Immunotherapy Small molecule drug developed by The Cleveland Clinic. It is currently FDA-approved for Treatment of various cancers. Also known as: Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon).
Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect.
Escalation Therapies Group involves gradually increasing the intensity of a treatment to achieve a desired therapeutic effect. Used for Treatment of various cancers.
At a glance
| Generic name | Escalation Therapies Group |
|---|---|
| Also known as | Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod) |
| Sponsor | The Cleveland Clinic |
| Drug class | Immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This approach allows for a more tailored and effective treatment plan, as the intensity of the therapy can be adjusted based on the individual's response. The goal is to maximize the therapeutic benefit while minimizing potential side effects.
Approved indications
- Treatment of various cancers
Common side effects
- Immune-related adverse events
Key clinical trials
- Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (PHASE1)
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. (PHASE1, PHASE2)
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Escalation Therapies Group CI brief — competitive landscape report
- Escalation Therapies Group updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI
Frequently asked questions about Escalation Therapies Group
What is Escalation Therapies Group?
How does Escalation Therapies Group work?
What is Escalation Therapies Group used for?
Who makes Escalation Therapies Group?
Is Escalation Therapies Group also known as anything else?
What drug class is Escalation Therapies Group in?
What development phase is Escalation Therapies Group in?
What are the side effects of Escalation Therapies Group?
Related
- Drug class: All Immunotherapy drugs
- Manufacturer: The Cleveland Clinic — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of various cancers
- Also known as: Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod)
- Compare: Escalation Therapies Group vs similar drugs
- Pricing: Escalation Therapies Group cost, discount & access